A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

This study is currently recruiting participants.
Verified March 2014 by Purdue Pharma LP
Sponsor:
Information provided by (Responsible Party):
Purdue Pharma LP
ClinicalTrials.gov Identifier:
NCT01427283
First received: August 30, 2011
Last updated: March 21, 2014
Last verified: March 2014
  Purpose

The primary objectives are to assess the analgesic efficacy of Oxycodone/Naloxone Controlled-release Tablets (OXN) compared to placebo and to assess the efficacy of OXN for the management of Opioid-induced Constipation (OIC) compared to Oxycodone Controlled-release Tablets (OXY) in subjects with moderate to severe pain due to chronic low back pain who require around-the-clock opioid therapy.


Condition Intervention Phase
Low Back Pain
Drug: Oxycodone/Naloxone controlled-release
Drug: Oxycodone HCl controlled-release
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy

Resource links provided by NLM:


Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • The "average pain over the last 24 hours" score at week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The "average pain over the last 24 hours" score at week 12 of the double-blind period comparing OXN to placebo. The score is based on an 11-point numerical rating scale (NRS): 0 = no pain, 10 = pain as bad as you can imagine.

  • Overall complete spontaneous bowel movement (CSBM) responder rates [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]
    The overall Complete Spontaneous Bowel Movement (CSBM) responder rates over the 12 week double-blind period comparing OXN to OXY


Secondary Outcome Measures:
  • Sleep Disturbance Subscale of the Medical Outcomes Study (MOS) Sleep Scale [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change (PGIC) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • CSBM Responder at least 50% of the weeks in the double-blind period [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]
  • Laxative-free Responder at least 50% of the weeks in the double-blind period [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 900
Study Start Date: August 2011
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OXN
Oxycodone/Naloxone controlled-release tablets (OXN)
Drug: Oxycodone/Naloxone controlled-release
Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
Active Comparator: OXY
Oxycodone HCl controlled-release tablets (OXY)
Drug: Oxycodone HCl controlled-release
Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Other Name: OxyContin
Placebo Comparator: Placebo
Placebo tablets to match OXN or OXY
Drug: Placebo
Placebo tablets to match OXN or OXY taken orally every 12 hours

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria include:

  • Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period;
  • The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation;
  • Subjects must be:

    1. On ongoing opioid analgesic medication for at least 4 weeks prior to the screening visit and on a stable dose of opioid analgesic medication equivalent to 20 to 160 mg (inclusive) of morphine per day for the last 2 weeks prior to the screening visit, or
    2. Taking 0 to less than 20 mg of morphine or its equivalent per day for the last 2 weeks prior to the screening visit due to OIC.

Subjects taking any dose of tramadol or wearing ≤ 70 mcg/h buprenorphine patch (as long as it does not exceed highest approved dose for buprenorphine in the country the study site is located) on a stable regimen for the last 2 weeks prior to the screening visit will also meet this criterion;

  • For subjects on <40 mg of morphine or equivalent per day, both the "average pain over the last 24 hours" and the "average pain over the past 14 days" scores at the screening visit must be ≥ 5;
  • Subjects must have a self-reported history of OIC as defined by having had while on opioids <3 complete spontaneous bowel movements (CSBMs) per week and 1 or more of the following for at least 25% of bowel movements (BMs):

    1. Hard or lumpy stools
    2. Straining during bowel movements
    3. A sensation of incomplete evacuation after bowel movements

A CSBM is defined as a spontaneous bowel movement (SBM) that is accompanied by the subject self-reporting a feeling of complete evacuation. An SBM is defined as a bowel movement occurring in the absence of laxative or enema use in the previous 24 hours;

  • Subjects must be willing to discontinue their current laxative regimen, including prokinetic drugs (e.g., metoclopramide);
  • Subjects must agree to the use of oral bisacodyl as their only laxative rescue medication;
  • Subjects who are willing and able to be compliant with the protocol, and who provide written informed consent.

Exclusion Criteria include:

  • Subjects with any contraindication or any history of hypersensitivity to oxycodone, naloxone, or other opioids. This does not include subjects who have experienced common opioid side effects (e.g., nausea, constipation);
  • Subjects with neurologic signs, or presumptive or confirmed compression of a spinal nerve root;
  • Subjects with acute spinal cord compression, acute compression fracture, seronegative spondyloarthropathy, acute nerve root compression, cauda equina compression, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection, tumor, or postherpetic neuralgia;
  • Subjects with gout, unless controlled on stable suppressive treatment with colchicine or uric-acid-lowering therapy without any attacks for ≥ 2 years and the subject has not been using NSAIDs or COX-2 inhibitors on a regular basis;
  • Subjects with pseudogout, psoriatic arthritis, active Lyme disease, rheumatoid arthritis or other inflammatory arthritis. Subjects with neuropathic conditions that have been painful or required therapy (such as gabapentin or other neuropathic pain treatments) within the past 3 months are also excluded;
  • Subjects with evidence of significant structural abnormalities of the gastrointestinal tract (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus, uncontrolled hypothyroidism);
  • Subjects with a history of prior chronic constipation (including functional constipation or pelvic floor dyssynergy) that was present for more than three months and that was not related to opioid use;
  • Subjects currently with clinically diagnosed diarrhea, defined as 3 stools/day that are loose or watery in nature within 2 weeks before visit 3;
  • Subjects with irritable bowel syndrome (IBS) or inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease);
  • Subjects who had surgery that may affect gastrointestinal motility or gastrointestinal pain within 2 months prior to the start of the screening period, or who plan such surgery during the study;
  • Subjects with a history of fecal incontinence;
  • Subjects who require ongoing therapy with medications (other than opioids) that have contributed to the subjects' constipation in the judgment of the investigator;
  • The subject must not have had any of the following within the indicated time periods before screening:

    • nerve/plexus block in the lumbar spine within 4 weeks
    • neuroablation in the lumbar spine within 6 weeks
    • Botulinum toxin injection for pain control in the lumbar spine within 3 months
    • steroid injections of the lumbar spine within 6 weeks or any intravenous or intramuscular steroid injections within 4 weeks;
  • Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study;
  • Subjects with a history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated;
  • Subjects with current uncontrolled depression or other uncontrolled psychiatric disorder (subjects with controlled depression or other psychiatric disorder must be on stable medication for at least 1 month prior to the screening visit to participate in the study);
  • Subjects currently taking, or who have taken naloxone, naltrexone, methylnaltrexone, or alvimopan within 10 days before the screening visit;
  • Subjects who have used any investigational medication within 30 days prior to the first dose of study medication;
  • Subjects who had received a monoamine oxidase inhibitor within the last 14 days prior to the screening visit;
  • Subjects with any condition in which opioids are contraindicated, such as severe respiratory depression with hypoxia and/or hypercapnia, severe chronic obstructive lung disease, cor pulmonale, severe bronchial asthma, or paralytic ileus;
  • Subjects with increase of intracranial pressure and/or epilepsy (not including history of pediatric febrile seizures);
  • Subjects with clinically significant cardiovascular disease or dysrhythmias;
  • Subjects with biliary tract disease, hypothyroidism, adrenal cortical insufficiency, or any other medical condition that in the investigator's opinion is inadequately treated and precludes entry into the study;
  • Subjects who, in the opinion of the Investigator, are unsuitable to participate in this study for any other reason;
  • Subjects who have received study drug in a clinical study of OXN or ONU.

Other protocol specific inclusion/exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01427283

Contacts
Contact: Patient Recruitment Specialist 1-855-253-3456 convergestudy@quintiles.com

  Hide Study Locations
Locations
United States, Alabama
Investigational Site Recruiting
Alabaster, Alabama, United States, 35007
Contact: Central Contact         
Investigational Site Recruiting
Birmingham, Alabama, United States, 35213
Contact: Central Contact         
Investigational Site Recruiting
Birmingham, Alabama, United States, 35216
Contact: Central Contact         
Investigational Site Recruiting
Foley, Alabama, United States, 36535
Contact: Central Contact         
Investigational Site Withdrawn
Homewood, Alabama, United States, 35209
Investigational Site Recruiting
Mobile, Alabama, United States, 36608
Contact: Central Contact         
United States, Arizona
Investigational Site Recruiting
Mesa, Arizona, United States, 85202
Contact: Central Contact         
Investigational Site Recruiting
Phoenix, Arizona, United States, 85020
Contact: Central Contact         
Investigational Site Recruiting
Phoenix, Arizona, United States, 85021
Contact: Central Contact         
Investigational Site Withdrawn
Phoenix, Arizona, United States, 85027
Investigational Site Terminated
Sun Lakes, Arizona, United States, 85248
Investigational Site Withdrawn
Tempe, Arizona, United States, 85282
Investigational Site Recruiting
Tucson, Arizona, United States, 85704
Contact: Central Contact         
Investigational Site Recruiting
Tucson, Arizona, United States, 85712
Contact: Central Contact         
United States, Arkansas
Investigational Site Withdrawn
Hot Springs, Arkansas, United States, 71901
Investigational Site Recruiting
Little Rock, Arkansas, United States, 72211
Contact: Central Contact         
Investigational Site Recruiting
Sherwood, Arkansas, United States, 72120
Contact: Central Contact         
United States, California
Investigational Site Recruiting
Anaheim, California, United States, 92801
Contact: Central Contact         
Investigational Site Recruiting
Anaheim, California, United States, 92804
Contact: Central Contact         
Investigational Site Recruiting
Artesia, California, United States, 90701
Contact: Central Contact         
Investigational Site Recruiting
Cerritos, California, United States, 90703
Contact: Central Contact         
Investigational Site Recruiting
Chino, California, United States, 91710
Contact: Central Contact         
Investigational Site Recruiting
El Cajon, California, United States, 92020
Contact: Central Contact         
Investigational Site Recruiting
Encino, California, United States, 91436
Contact: Central Contact         
Investigational Site Recruiting
Fountain Valley, California, United States, 92708
Contact: Central Contact         
Investigational Site Recruiting
Fresno, California, United States, 93720
Contact: Central Contact         
Investigational Site Withdrawn
Fresno, California, United States, 93726
Investigational Site Recruiting
Garden Grove, California, United States, 92844
Contact: Central Contact         
Investigational Site Recruiting
Garden Grove, California, United States, 92843
Contact: Central Contact         
Investigational Site Recruiting
Laguna Hills, California, United States, 92653
Contact: Central Contact         
Investigational Site Withdrawn
Laguna Hills, California, United States, 92637
Investigational Site Recruiting
Lakewood, California, United States, 90712
Contact: Central Contact         
Investigational Site Recruiting
Lincoln, California, United States, 95648
Contact: Central Contact         
Investigational Site Recruiting
Lomita, California, United States, 90717
Contact: Central Contact         
Investigational Site Recruiting
Long Beach, California, United States, 90806
Contact: Central Contact         
Investigational Site Withdrawn
Los Gatos, California, United States, 95032
Investigational Site Recruiting
Oceanside, California, United States, 92054
Contact: Central Contact         
Investigational Site Recruiting
Orange, California, United States, 92868
Contact: Central Contact         
Investigational Site Recruiting
Paramount, California, United States, 90723
Contact: Central Contact         
Investigational Site Withdrawn
Richmond, California, United States, 94806
Investigational Site Withdrawn
Sacramento, California, United States, 95842
Investigational Site Recruiting
Sacramento, California, United States, 95823
Contact: Central Contact         
Investigational Site Recruiting
San Bernardino, California, United States, 92408
Contact: Central Contact         
Investigational Site Recruiting
San Diego, California, United States, 92114
Contact: Central Contact         
Investigational Site Recruiting
San Diego, California, United States, 92103
Contact: Central Contact         
Investigational Site Recruiting
Thousand Oaks, California, United States, 91360
Contact: Central Contact         
Investigational Site Recruiting
Torrance, California, United States, 90509
Contact: Central Contact         
Investigational Site Withdrawn
Valley Village, California, United States, 91607
United States, Colorado
Investigational Site Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Central Contact         
Investigational Site Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Central Contact         
Investigational Site Recruiting
Denver, Colorado, United States, 80246
Contact: Central Contact         
Investigational Site Recruiting
Golden, Colorado, United States, 80401
Contact: Central Contact         
United States, Connecticut
Investigational Site Withdrawn
Waterbury, Connecticut, United States, 06708
United States, Florida
Investigational Site Recruiting
Aventura, Florida, United States, 33180
Contact: Central Contact         
Investigational Site Recruiting
Bradenton, Florida, United States, 34209
Contact: Central Contact         
Investigational Site Recruiting
Chiefland, Florida, United States, 32626
Contact: Central Contact         
Investigational Site Withdrawn
Clearwater, Florida, United States, 33765
Investigational Site Recruiting
Clermont, Florida, United States, 34711
Contact: Central Contact         
Investigational Site Recruiting
Daytona Beach, Florida, United States, 32117
Contact: Central Contact         
Investigational Site Recruiting
Deland, Florida, United States, 32720
Contact: Central Contact         
Investigational Site Recruiting
Edgewater, Florida, United States, 32132
Contact: Central Contact         
Investigational Site Recruiting
Ft. Lauderdale, Florida, United States, 33316
Contact: Central Contact         
Investigational Site Recruiting
Ft. Myers, Florida, United States, 33916
Contact: Central Contact         
Investigational Site Recruiting
Hialeah, Florida, United States, 33010
Contact: Central Contact         
Investigational Site Recruiting
Hialeah, Florida, United States, 33012
Contact: Central Contact         
Investigational Site Recruiting
Inverness, Florida, United States, 34452
Contact: Central Contact         
Investigational Site Recruiting
Jacksonville, Florida, United States, 32216
Contact: Central Contact         
Investigational Site Withdrawn
Jacksonville, Florida, United States, 32216
Investigational Site Withdrawn
Jacksonville, Florida, United States, 32258
Investigational Site Terminated
Jacksonville, Florida, United States, 32257
Investigational Site Recruiting
Jacksonville, Florida, United States, 32256
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33015
Contact: Central Contact         
Investigational Site Withdrawn
Miami, Florida, United States, 33126
Investigational Site Recruiting
Miami, Florida, United States, 33185
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33155
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33136
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33126
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33144
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33165
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33145
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33125
Contact: Central Contact         
Investigational Site Recruiting
Miami, Florida, United States, 33135
Contact: Central Contact         
Investigational Site Recruiting
Miami Beach, Florida, United States, 33140
Contact: Central Contact         
Investigational Site Recruiting
Naples, Florida, United States, 34113
Contact: Central Contact         
Investigational Site Terminated
Naples, Florida, United States, 34110
Investigational Site Withdrawn
New Port Richey, Florida, United States, 34652
Investigational Site Terminated
New Smyrna Beach, Florida, United States, 32168
Investigational Site Recruiting
North Miami, Florida, United States, 33161
Contact: Central Contact         
Investigational Site Recruiting
Oldsmar, Florida, United States, 34677
Contact: Central Contact         
Investigational Site Recruiting
Orlando, Florida, United States, 32806
Contact: Central Contact         
Investigational Site Recruiting
Oviedo, Florida, United States, 32765
Contact: Central Contact         
Investigational Site Recruiting
Plantation, Florida, United States, 33317
Contact: Central Contact         
Investigational Site Withdrawn
Port Orange, Florida, United States, 32129
Investigational Site Recruiting
Tamarac, Florida, United States, 33321
Contact: Central Contact         
Investigational Site Withdrawn
Tampa, Florida, United States, 33613
Investigational Site Recruiting
Tampa, Florida, United States, 33607
Contact: Central Contact         
Investigational Site Withdrawn
Wellington, Florida, United States, 33414
Investigational Site Recruiting
West Palm Beach, Florida, United States, 33409
Contact: Central Contact         
Investigational Site Withdrawn
Winter Park, Florida, United States, 32789
United States, Georgia
Investigational Site Recruiting
Atlanta, Georgia, United States, 30308
Contact: Central Contact         
Investigational Site Recruiting
Austell, Georgia, United States, 30106
Contact: Central Contact         
Investigational Site Withdrawn
Canton, Georgia, United States, 30114
Investigational Site Withdrawn
Marietta, Georgia, United States, 30060
Investigational Site Recruiting
Snellville, Georgia, United States, 30078
Contact: Central Contact         
United States, Idaho
Investigational Site Recruiting
Boise, Idaho, United States, 83713
Contact: Central Contact         
Investigational Site Recruiting
Boise, Idaho, United States, 83704
Contact: Central Contact         
Investigational Site Withdrawn
Boise, Idaho, United States, 83713
Investigational Site Withdrawn
Meridian, Idaho, United States, 83642
United States, Illinois
Investigational Site Recruiting
Chicago, Illinois, United States, 60657
Contact: Central Contact         
Investigational Site Recruiting
Chicago, Illinois, United States, 60616
Contact: Central Contact         
Investigational Site Recruiting
Chicago, Illinois, United States, 60622
Contact: Central Contact         
United States, Indiana
Investigational Site Terminated
Evansville, Indiana, United States, 47714
Investigational Site Recruiting
Indianapolis, Indiana, United States, 46250
Contact: Central Contact         
Investigational Site Recruiting
Michigan City, Indiana, United States, 46360
Contact: Central Contact         
United States, Kansas
Investigational Site Recruiting
Wichita, Kansas, United States, 67203
Contact: Central Contact         
United States, Kentucky
Investigational Site Recruiting
Edgewood, Kentucky, United States, 41017
Contact: Central Contact         
Investigational Site Withdrawn
Madisonville, Kentucky, United States, 42431
United States, Louisiana
Investigational Site Withdrawn
Covington, Louisiana, United States, 70435
Investigational Site Recruiting
Lake Charles, Louisiana, United States, 70601
Contact: Central Contact         
Investigational Site Withdrawn
Marrero, Louisiana, United States, 70072
Investigational Site Withdrawn
Metairie, Louisiana, United States, 70006
Investigational Site Recruiting
Monroe, Louisiana, United States, 71201
Contact: Central Contact         
Investigational Site Recruiting
New Orleans, Louisiana, United States, 70119
Contact: Central Contact         
United States, Maryland
Investigational Site Recruiting
Pikesville, Maryland, United States, 21208
Contact: Central Contact         
United States, Massachusetts
Investigational Site Recruiting
Brockton, Massachusetts, United States, 02301
Contact: Central Contact         
Investigational Site Withdrawn
Fall River, Massachusetts, United States, 02720
Investigational Site Recruiting
Worcester, Massachusetts, United States, 01605
Contact: Central Contact         
United States, Missouri
Investigational Site Recruiting
Florissant, Missouri, United States, 63031
Contact: Central Contact         
United States, Nevada
Investigational Site Recruiting
Las Vegas, Nevada, United States, 89119
Contact: Central Contact         
United States, New Jersey
Investigational Site Recruiting
Atco, New Jersey, United States, 08004
Contact: Central Contact         
Investigational Site Withdrawn
Belvidere, New Jersey, United States, 07823
United States, New York
Investigational Site Withdrawn
Cedarhurst, New York, United States, 11516
Investigational Site Recruiting
Great Neck, New York, United States, 11023
Contact: Central Contact         
Investigational Site Recruiting
Kew Gardens, New York, United States, 11415
Contact: Central Contact         
Investigational Site Recruiting
New York, New York, United States, 10023
Contact: Central Contact         
Investigational Site Withdrawn
North Massapequa, New York, United States, 11758
Investigational Site Recruiting
Rochester, New York, United States, 14618
Contact: Central Contact         
Investigational Site Recruiting
Williamsville, New York, United States, 14221
Contact: Central Contact         
United States, North Carolina
Investigational Site Recruiting
Durham, North Carolina, United States, 27710
Contact: Central Contact         
Investigational Site Recruiting
Elkin, North Carolina, United States, 28621
Contact: Central Contact         
Investigational Site Recruiting
High Point, North Carolina, United States, 27262
Contact: Central Contact         
Investigational Site Recruiting
Winston Salem, North Carolina, United States, 27103
Contact: Central Contact         
Investigational Site Recruiting
Winston-Salem, North Carolina, United States, 27103
Contact: Central Contact         
United States, Ohio
Investigational Site Recruiting
Columbus, Ohio, United States, 43213
Contact: Central Contact         
Investigational Site Recruiting
Dayton, Ohio, United States, 45406
Contact: Central Contact         
Investigational Site Recruiting
Moraine, Ohio, United States, 45439
Contact: Central Contact         
Investigational Site Recruiting
Toledo, Ohio, United States, 43614
Contact: Central Contact         
United States, Oklahoma
Investigational Site Recruiting
Oklahoma City, Oklahoma, United States, 73119
Contact: Central Contact         
Investigational Site Recruiting
Oklahoma City, Oklahoma, United States, 73103
Contact: Central Contact         
Investigational Site Recruiting
Oklahoma City, Oklahoma, United States, 73109
Contact: Central Contact         
United States, Oregon
Investigational Site Recruiting
Eugene, Oregon, United States, 97404
Contact: Central Contact         
United States, Pennsylvania
Investigational Site Recruiting
Jenkintown, Pennsylvania, United States, 19046
Contact: Central Contact         
Investigational Site Withdrawn
Johnstown, Pennsylvania, United States, 15904
Investigational Site Recruiting
Levittown, Pennsylvania, United States, 19056
Contact: Central Contact         
Investigational Site Recruiting
Mechanicsburg, Pennsylvania, United States, 17055
Contact: Central Contact         
Investigational Site Withdrawn
Phoenixville, Pennsylvania, United States, 19460
Investigational Site Recruiting
Pittsburgh, Pennsylvania, United States, 15215
Contact: Central Contact         
Investigational Site Recruiting
Red Lion, Pennsylvania, United States, 17356
Contact: Central Contact         
Investigational Site Recruiting
State College, Pennsylvania, United States, 16801
Contact: Central Contact         
Investigational Site Withdrawn
Tipton, Pennsylvania, United States, 16684
United States, Rhode Island
Investigational Site Withdrawn
Cranston, Rhode Island, United States, 02920
Investigational Site Recruiting
Warwick, Rhode Island, United States, 02886
Contact: Central Contact         
United States, South Carolina
Investigational Site Recruiting
Charleston, South Carolina, United States, 29406
Contact: Central Contact         
Investigational Site Withdrawn
Greer, South Carolina, United States, 29650
Investigational Site Recruiting
Myrtle Beach, South Carolina, United States, 29588
Contact: Central Contact         
Investigational Site Withdrawn
Spartanburg, South Carolina, United States, 29303
United States, South Dakota
Investigational Site Recruiting
Rapid City, South Dakota, United States, 57702
Contact: Central Contact         
United States, Tennessee
Investigational Site Recruiting
Jackson, Tennessee, United States, 38305
Contact: Central Contact         
United States, Texas
Investigational Site Recruiting
Allen, Texas, United States, 75013
Contact: Central Contact         
Investigational Site Withdrawn
Athens, Texas, United States, 75751
Investigational Site Withdrawn
Austin, Texas, United States, 78756
Investigational Site Recruiting
Austin, Texas, United States, 78731
Contact: Central Contact         
Investigational Site Recruiting
Dallas, Texas, United States, 75231
Contact: Central Contact         
Investigational Site Recruiting
Dallas, Texas, United States, 75203
Contact: Central Contact         
Investigational Site Recruiting
Dallas, Texas, United States, 75251
Contact: Central Contact         
Investigational Site Recruiting
Dallas, Texas, United States, 75218
Contact: Central Contact         
Investigational Site Recruiting
Houston, Texas, United States, 77098
Contact: Central Contact         
Investigational Site Recruiting
Houston, Texas, United States, 77062
Contact: Central Contact         
Investigational Site Recruiting
Houston, Texas, United States, 77074
Contact: Central Contact         
Investigational Site Recruiting
Houston, Texas, United States, 77065
Contact: Central Contact         
Investigational Site Withdrawn
Houston, Texas, United States, 77074
Investigational Site Recruiting
McKinney, Texas, United States, 75070
Contact: Central Contact         
Investigational Site Recruiting
North Richland Hills, Texas, United States, 76180
Contact: Central Contact         
Investigational Site Withdrawn
Plano, Texas, United States, 75075
Investigational Site Withdrawn
Spring, Texas, United States, 77386
Investigational Site Recruiting
Tomball, Texas, United States, 77375
Contact: Central Contact         
United States, Utah
Investigational Site Withdrawn
Clinton, Utah, United States, 84015
Investigational Site Recruiting
Orem, Utah, United States, 84058
Contact: Central Contact         
Investigational Site Recruiting
Salt Lake City, Utah, United States, 84102
Contact: Central Contact         
Investigational Site Withdrawn
Salt Lake City, Utah, United States, 84107
Investigational Site Recruiting
Salt Lake City, Utah, United States, 84124
Contact: Central Contact         
Investigational Site Withdrawn
West Jordan, Utah, United States, 84088
United States, Virginia
Investigational Site Recruiting
Danville, Virginia, United States, 24541
Contact: Central Contact         
Investigational Site Recruiting
Midlothian, Virginia, United States, 23114
Contact: Central Contact         
Investigational Site Recruiting
Richmond, Virginia, United States, 23220
Contact: Central Contact         
Investigational Site Withdrawn
Richmond, Virginia, United States, 23219
Investigational Site Withdrawn
Virginia Beach, Virginia, United States, 23454
United States, Washington
Investigational Site Recruiting
Bothell, Washington, United States, 98011
Contact: Central Contact         
Sponsors and Collaborators
Purdue Pharma LP
  More Information

No publications provided

Responsible Party: Purdue Pharma LP
ClinicalTrials.gov Identifier: NCT01427283     History of Changes
Other Study ID Numbers: ONU3705, 2011-005061-20
Study First Received: August 30, 2011
Last Updated: March 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Purdue Pharma LP:
Low back pain
Chronic pain
Opioid
Constipation
Moderate to severe

Additional relevant MeSH terms:
Back Pain
Constipation
Low Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Analgesics
Oxycodone
Naloxone
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Narcotic Antagonists
Narcotics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on April 17, 2014